TABLE 3.
Risk factors for renal failurea
| Characteristic | Value(s) for: |
P | ||
|---|---|---|---|---|
| Entire cohort (n = 115) | Patients with renal failure |
|||
| Yes (n = 25) | No (n = 90) | |||
| No. (%) of female patients | 49 (42.6) | 14 (56) | 35 (38.9) | 0.12 |
| Mean ± SD age (yr) | 57 ± 17 | 55 ± 16 | 57 ± 18 | 0.51 |
| Median (IQR) wt (kg) | 71 (60–90) | 73 (65–90) | 70 (60–90) | 0.66 |
| Median (IQR) PMB dose (mg/kg/day) | 3.5 (3.1–4.2) | 3.61 (3.2–4) | 3.5 (3.1–4.3) | 0.74 |
| Median (IQR) total daily dose (mg) | 271 (246–300) | 283 (200–300) | 270 (249–300) | 0.68 |
| No. (%) of patients in ICU | 54 (46.9) | 14 (56) | 40 (44.4) | 0.30 |
| Median (IQR) duration of treatment (days) | 8 (5–12) | 10 (6–14.5) | 7 (4–11) | 0.06 |
| No. (%) of patients with bacteremia | 22 (19.1) | 3 (12) | 19 (21.1) | 0.39 |
| Median (IQR) Charlson comorbidity index | 4 (2–6) | 4 (2–6) | 4 (2–6) | 0.98 |
| No. (%) of patients receiving: | ||||
| A vasoactive drug | 50 (43.5) | 16 (64) | 34 (37.8) | 0.02 |
| PMB alone | 10 (8.6) | 0 | 10 (11.1) | 0.11 |
| Other nephrotoxic drugsb | 61 (53) | 18 (72) | 43 (47.8) | 0.04 |
| Median (IQR) creatinine concn on day 1 (mg/dl) | 0.87 (0.56–1.35) | 0.74 (0.51–0.97) | 0.91 (0.59–1.55) | 0.04 |
| Median (IQR) creatinine clearance on day 1 (ml/min) | 88 (50–143) | 129 (71–175) | 80 (49–136) | 0.02 |
a
ICU, intensive care unit; PMB, polymyxin B; IQR, interquartile range.
b
Vancomycin (n = 51 patients), aminoglycosides (n = 21 patients), and amphotericin B (n = 5 patients).